HEAT-STABLE OXYTOCIN TO PREVENT MATERNAL DEATH IN CHILDBIRTH

[mango]

Mintaka's Robin Offord and Oliver Hartley are on the Advisor Board of Orion Biotechnology, a company with sufficient capital, and which recently in September, acquired Mintaka's 5P12-RANTES molecule, including its patent portfolio for an undisclosed amount.
Perhaps our friends at Mintaka Foundation have aquired the much needed and necessary capital to advance the Heat Stable Dry Powder Oxytocin by Oral Inhalation to the required Phase 1 safety trial. Mintaka and MannKind have spent years on this project, maybe this was the break Mintaka has been patiently waiting for.


• Robin Offord
Senior Research Advisor

• Oliver Hartley
Senior Research Advisor

orionbiotechnology.com



Orion Biotechnology acquires patent portfolio for potent CCR5 chemokine antagonist

Ottawa, Canada September 5th, 2018

Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that its subsidiary, Orion Biotechnology Switzerland Sàrl, has successfully closed a transaction with the Mintaka Medical Research Foundation for the acquisition of the 5P12-RANTES molecule. 5P12-RANTES is a potent CCR5 chemokine antagonist which Orion will develop in a number of areas, including; immuno-oncology, multiple sclerosis and HIV prevention.

The acquisition includes its worldwide patent portfolio, and has resulted in a partnership with the Geneva, Switzerland based Mintaka Medical Research Foundation, and the Wellcome Trust of London, England. No financial details of the transaction were released.

“We are thrilled to add the enormous potential of the 5P12-RANTES portfolio to our pipeline” said Mark Groper, President and CEO of Orion Biotechnology. “It adds depth to our pipeline, strengthens our intellectual property portfolio, and provides the basis for the development of several additional novel immunotherapies”.

“I’m excited that we were able to successfully form this partnership with Orion Biotechnology” said Robin Offord, Executive Director of the Mintaka Medical Research Foundation. “Mintaka looks forward to continuing its work on humanitarian (anti-HIV) uses of 5P12-RANTES with the help of the highly innovative and capable team at Orion and the substantial resources that they bring to the table.  
Also, 5P12-RANTES has surprised us all by its potential in a wide range of other medical indications and Orion is well placed to exploit these applications to the full”.

Daniel Gill, from Wellcome’s Innovations team said: “HIV remains a significant global health issue and we are pleased to continue our collaboration on the development of 5P12-RANTES with Orion Biotechnology.  

5P12-RANTES has significant potential in other areas of unmet need and we are excited that Orion will expand development of the molecule in other therapeutic areas such as immune-oncology and multiple sclerosis.”

orionbiotechnology.com/news/orion-biotechnology-acquires-patent-portfolio-for-potent-ccr5-chemokine-antagonist/



HEAT-STABLE DRY POWDER OXYTOCIN BY MINTAKA FOUNDATION AND MANNKIND CORP FOR THE PREVENTION OF MATERNAL DEATH IN CHILDBIRTH

The Problem

Of the approximately half a million women who die annually from causes related to pregnancy and childbirth, about 99% live in developing countries. For instance, in Chad, on average one girl in 14 who survives growing up will, later in life, die from such causes. The corresponding figure in the developed world is one in 4900 (numbers from WHO – Nov 2015).
At least a quarter of these maternal deaths are a result of uncontrolled bleeding after giving birth.


Our Solution

Many deaths by bleeding could be prevented by an immediate intravenous injection of the drug oxytocin. However, oxytocin is unstable in warm climates and trained staff are not always available to give injections. With MannKind Corporation (USA), we have formulated oxytocin in a dry, stabilized form which can be loaded into a robust, very inexpensive, disposable inhaler, eliminating at the same time the need for injection. Administration by inhalation at last makes treatment possible outside centres with trained medical staff.


Next Steps

Some 98% of our formulation of oxytocin survives 8 months at 40°C, and the inhaler has proved a highly efficient means of delivery. The next step is to design and then execute a clinical safety trial in a developed county (medicines should not be safety-tested on fragile populations). If our expectation that there will be no safety issues proves justified, the way will then be open to forming a product development partnership to take the product to market.


Anticipated Impact

A substantial decrease in the ~140,000 deaths per year and in the number of women (currently 1,600,000) who survive, but in a seriously weakened state. The return to their families of women in good health, ready to care for their children and assume once again their responsibilities in their community.

www.mintakafoundation.org/our-projects/maternal-health/



HEAT- STABLE OXYTOCIN TO PREVENT MATERNAL DEATH IN CHILDBIRTH

In this work, heat stable dry powders of oxytocin (OT) suitable for delivery by oral inhalation were prepared.

www.mintakafoundation.org/wp-content/uploads/mannkind-Oxytocin-manuscript-reprint-15_0318.pdf



HEAT-STABLE DRY POWDER PHARMACEUTICAL COMPOSITIONS AND METHODS

8/9/2018

Disclosed herein are heat-stable dry powder compositions and methods for delivering biodegradable substances, including peptides and proteins, and systems and methods for delivering the dry powders. In particular, the dry powders are preferably intended for pulmonary delivery by inhalation to treat certain disorders and/or diseases, including post-partum hemorrhaging.

patentscope.wipo.int/search/en/detail.jsf?docId=US224374923&tab=NATIONALBIBLIO&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=FP%3A%28Andrea+Leone-Bay%29&recNum=2&maxRec=359

[cedafuntennis]

Where is the money for Mannkind in this? Good deed,great indeed,but were not in position of charity providers to the world just yet. Clinical trials in developed countries are extremely expensive and time consuming. The UN could fund this but they are too busy supporting failed dictators and cimmunists while bashing the US and Israel so don't look at them to do their job.

[mango]

Oct 28, 2018 12:26:17 GMT -5 cedafuntennis said:

Where is the money for Mannkind in this? Good deed,great indeed,but were not in position of charity providers to the world just yet. Clinical trials in developed countries are extremely expensive and time consuming. The UN could fund this but they are too busy supporting failed dictators and cimmunists while bashing the US and Israel so don't look at them to do their job.

The cost for the Phase 1 safety study would be approximately $2M.

The cost of goods is estimated to be between ~$0.70/dose and ~$0.30/dose.

The cost-effectiveness would assumably generate major endorsements and purchases by sorereign governments.

The addressable market for 2020 wordwide is 133million births/yr with the high-risk regions being Africa, South-Cental and South-Eastern Asia with approximately 88million births/yr and this would be the initial target population.

The model for the high-risk regions looks something like this:

• Region: Africa, South-Cental and South-Eastern Asia

• Million births/yr: 88.3

• Net target revenue per unit sale (US$): US$0.5

• Addressable market (net) approx: US$44 million

• Target % penetration at year 3 after licensure: 5.0%

• Target net revenue at year 3 after licensure: US$2.2 million


I'd say that based on the model above, the return on investment looks rather soigne for an humanitarian effort, especially considering all the lives that would be saved.


Love and Light ✌️🌍